A

    Alaunos Therapeutics Inc (TCRT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.70
    +0.09 (+5.92%)

    Market Cap: $4.08M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    61%(19/31)
    Avg Surprise
    -17.21%
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    		$-0.41N/AN/ABeat+11.5%
    Sep 25
    		$-0.55$0.00N/AMiss+21.9%
    Jun 25
    		$-0.63N/AN/ABeat+10.7%
    Mar 25
    		$-0.67N/AN/ABeat+96.1%
    Dec 24
    		$-0.46N/AN/ABeat+5.4%
    Sep 24
    		$-0.70N/AN/ABeat+84.0%
    Jun 24
    		$-0.71$0.00N/ABeat+88.2%
    Mar 24
    		$-17.09$-4.50-279.78%Miss-184.8%
    Dec 23
    		$-0.49$-0.45-8.89%Miss-1125.0%
    Sep 23
    		$-4.41$-5.25+16.00%Beat+26.5%
    Jun 23
    		$-6.00$-6.75+11.11%Beat+20.0%
    Mar 23
    		$-6.00$-6.60+9.09%Beat+20.0%
    Dec 22
    		$-0.04$-0.07+42.86%Beat+20.0%
    Sep 22
    		$-6.00$-10.75+44.19%Beat+63.6%
    Jun 22
    		$-7.50$-10.25+26.83%Beat+54.5%
    Mar 22
    		$-7.50$-9.90+24.24%Beat+50.0%
    Dec 21
    		$-0.05$-0.08+37.50%Beat+54.5%
    Sep 21
    		$-16.50$-18.86+12.51%Beat-10.0%
    Jun 21
    		$-16.50$-17.57+6.09%Beat-22.2%
    Mar 21
    		$-15.00$-15.81+5.12%Beat-11.1%
    Dec 20
    		$-0.11$-0.10-10.00%Miss-22.2%
    Sep 20
    		$-15.00$-13.49-11.19%Miss+76.7%
    Jun 20
    		$-13.50$-13.75+1.82%Beat+0.0%
    Mar 20
    		$-13.50$-12.75-5.88%Miss-12.5%
    Dec 19
    		$-0.09$-0.08-12.50%Miss-12.5%
    Sep 19
    		$-64.50$-13.50-377.78%Miss-230.8%
    Jun 19
    		$-13.50$-12.24-10.29%Miss+25.0%
    Mar 19
    		$-12.00$-12.30+2.44%Beat+46.7%
    Dec 18
    		$-0.08$-0.11+27.27%Beat+38.5%
    Sep 18
    		$-19.50$-16.73-16.56%Miss+0.0%
    Jun 18
    		$-18.00$-18.52+2.81%Beat+7.7%
    Mar 18
    		$-22.50$-19.06-18.05%Miss+0.0%
    Dec 17
    		$-0.13$-0.14+7.14%Beat-18.2%
    Sep 17
    		$-19.50$-20.29+3.89%Beat-18.2%
    Jun 17
    		$-19.50$-18.43-5.81%Miss-
    Mar 17
    		$-22.50$-14.22-58.23%Miss-
    Dec 16
    		$-0.11$-0.11+0.00%Beat-
    Sep 16
    		$-16.50$-16.60+0.60%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.75EV/EBITDA-3.55x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-135233.00%
    ROE-185.90%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio0.77xQuick Ratio0.77x
    Trading Statistics
    Beta-0.96Avg Volume12.47K
    52-Week High$4.5952-Week Low$1.55

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.76
    SMA 20$1.86
    SMA 50$1.98
    SMA 200$2.73
    EMA 10$1.75
    EMA 20$1.82
    EMA 50$1.99
    EMA 200$2.46

    MACD

    Line: -0.09Signal: -0.07Hist: -0.02

    ADX

    ADX: 29.1+DI: 8.3-DI: 25.9

    Aroon & PSAR

    Aroon Up60.0
    Aroon Down96.0
    PSAR$1.85

    Bollinger Bands

    Upper Band$2.12
    Lower Band$1.61
    %B Position2734%(Upper)
    Band Width0.18

    RSI (14-Day)

    Neutral
    36.5

    Momentum Oscillators

    Stoch %K16.8
    Stoch %D17.3
    Williams %R-70.0
    ROC (10d)-11.0%
    Momentum-0.21
    CCI (20d)-123.9
    MFI (14d)24.6

    Volatility Measures

    ATR (14d)$0.11(6.7%)
    StdDev (20d)0.13
    Hist Vol49.7%(High)

    Volume Flow

    VWAP$1.67
    OBV41.4M
    AD Line-9.9M
    CMF (20d)-0.076

    Volume Metrics

    Avg Vol (20d)12.8K
    Vol Ratio1.0x
    VWMA (20d)$1.81

    Pivot Points

    R3$1.85
    R2$1.78
    R1$1.69
    Pivot Point$1.62
    S1$1.53
    S2$1.46
    S3$1.37

    Advanced Oscillators

    TSI-32.10
    Ultimate Osc49.7
    KST-110.29

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$3,000$0$0$2,000$5,000$0$4,000$1,000$1,000$0
    Cost of Revenue$0$0$-185,000$0$0$0N/A$0$0$0N/A$0
    Gross Profit$0$0$3,000$0$0$2,000$5,000$0$4,000$1,000$1,000$0
    Operating Expenses$952,000$1.01M$910,000$1.19M$1.04M$1.09M$759,000$1.15M$1.17M$1.74M$7.95M$8.66M
    R&D$388,000$427,000$362,000$469,000$185,000$347,000$-87,000$143,000$180,000$126,000$933,000$3.66M
    SG&A$564,000$585,000$548,000$718,000$854,000$747,000$846,000$1.01M$990,000$1.62M$2.43M$3.58M
    Operating Income$-952,000$-1,012,000$-907,000$-1,187,000$-1,039,000$-1,092,000$-754,000$-1,150,000$-1,166,000$-1,742,000$-7,949,000$-8,664,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$12,000$0$0$0$0$0$0$0
    Income Before Tax$-952,000$-1,006,000$-862,000$-1,159,000$-1,051,000$-1,073,000$-741,000$-1,127,000$-1,129,000$-1,682,000$-7,843,000$-8,476,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-952,000$-1,006,000$-893,000$-1,159,000$-1,051,000$-1,073,000$-741,000$-1,127,000$-1,129,000$-1,682,000$-7,843,000$-8,476,000
    EBITDA$-943,000$-998,000$-855,000$-1,159,000$-1,051,000$-1,073,000$-742,000$-1,127,000$-1,129,000$-1,682,000$-7,602,000$-7,797,000
    EBIT$-952,000$-1,006,000$-862,000$-1,159,000$-1,051,000$-1,073,000$-741,000$-1,127,000$-1,129,000$-1,682,000$-7,843,000$-8,476,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TCRT

    News

    Alaunos Therapeutics, Inc. Q2 2026: Revenue $0K, Net loss $988K, EPS $(0.41) — 10-Q Summary

    Alaunos Therapeutics, Inc. reported its Q2 2026 financial results, showing no revenue and a reduced net loss of $988K, or $(0.41) diluted net loss per share. The company is advancing its preclinical metabolic programs, with lead oral candidate ALN1003 demonstrating positive results in weight loss and metabolic efficacy in a proof-of-concept study. Further development is dependent on securing additional funding or partnerships.

    TradingView•8/14/26•
    Somewhat-Bullish

    Alaunos Therapeutics (TCRT) CEO granted 4,363 shares in lieu of cash salary

    Alaunos Therapeutics, Inc. reported that its CEO, Holger Weis, received 4,363 shares of common stock on August 6, 2026, as part of his compensation package, issued in lieu of a cash salary. These shares were valued at $2.01 per share. Following this transaction, Weis directly holds 25,483 shares of the company's common stock.

    Stock Titan•8/11/26•
    Neutral

    Enterprise value to EBITDA forward of Alaunos Therapeutics, Inc. – NASDAQ:TCRT

    This article provides the enterprise value to EBITDA forward for Alaunos Therapeutics, Inc. (NASDAQ: TCRT). It is a financial data point presented by TradingView, indicating a specific valuation metric for the biotechnology company. The content appears to be a financial data page rather than an analytical article.

    TradingView•8/6/26•
    Neutral

    Enterprise value to EBIT forward of Alaunos Therapeutics, Inc. – NASDAQ:TCRT

    This article provides a brief financial snippet for Alaunos Therapeutics, Inc. (NASDAQ: TCRT), focusing on its enterprise value to EBIT forward metric. The content itself is very minimal, essentially a placeholder or header indicating where detailed financial information would typically be presented on the TradingView platform. It does not offer any specific financial figures or analysis within the provided text.

    TradingView•8/1/26•
    Neutral

    Alaunos Therapeutics Inc (TCRT) Financial Health: Profitability & Balance Sheet Analysis

    Alaunos Therapeutics Inc (TCRT) has a current financial score of 7.34, ranking 128th out of 384 in the Biotechnology & Medical Research industry, indicating robust financial status but low operating efficiency. Its latest quarterly revenue saw a 100.00% year-over-year decrease, and net profit decreased by 6.24% year-over-year. The financial analysis highlights areas like Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns, noting that relevant data for several categories have not yet been disclosed by the company.

    TradingKey•7/30/26•
    Somewhat-Bearish

    Frequently Asked Questions About TCRT

    Does TCRT pay dividends?
    Alaunos Therapeutics Inc (TCRT) does not currently pay a regular dividend.
    What is TCRT's market cap?
    Alaunos Therapeutics Inc (TCRT) has a market capitalization of $4.08M with a current stock price of $1.70.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In